Narrator 19:08 Be inspired, supported, and empowered
Here in the U.S.: 4 million people are disabled from it and out of work, 14 million people still have long COVID symptoms, 22% with long COVID were unable to work due to ill health (many others simply lost their jobs), 45% with long COVID had to reduce their work hours
With Mondays approval, Yesintek joins a growing group of Stelara copycats poised to challenge the blockbuster drug next year
Harder-Lauridsen Nina, M
Injectable: The researchers used newer small-molecule oral GLP-1 drugs, which are more stable and less expensive than injectables
The medication is accessible across all 50 states, and patients can increase their dose as needed without price increases, following the principle that doses may rise but pricing remains flat